Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.39 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 9/20 | 0.37 |
| ▸ | CTSS | P25774 | 6/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2449068 | 0.87 | ITGB3 (0.44) | PADI1PADI4CTSLITGB3ITGA2B | |
| SCHEMBL2449064 | 0.87 | ITGB3 (0.44) | PADI1PADI4CTSLITGB3ITGA2B | |
| SCHEMBL10164354 | 0.85 | CTSK (0.43) | PADI1PADI4CTSLITGB3ITGA2B | |
| SCHEMBL10164317 | 0.84 | PADI1 (0.38) | PADI1PADI4CTSLITGB3ITGA2B | |
| SCHEMBL20179503 | 0.79 | ITGB3 (0.48) | ITGB3ITGA2BCTSKCTSSDRD2 | |
| SCHEMBL28937294 | 0.79 | ITGB3 (0.48) | ITGB3ITGA2BCTSKCTSSDRD2 | |
| SCHEMBL1076354 | 0.76 | ITGA4 (0.41) | CTSLITGB3ITGA2BNFKB1NFKB2 | |
| SCHEMBL30819570 | 0.76 | DRD2 (0.43) | CTSLITGB3ITGA2BNFKB1NFKB2 | |
| SCHEMBL21033562 | 0.76 | DRD2 (0.59) | CTSKDRD2 | |
| SCHEMBL21409064 | 0.75 | CTSK (0.44) | CTSLITGB3ITGA2BCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689353-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| EP-3150586-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| EP-2487163-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2487162-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2487161-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2487167-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2487166-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2487168-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2487161-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2487164-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8148374-B2 | Concurrent administering of drugs; side effect reduction | GILEAD SCIENCES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100189687-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100189687-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2008103949-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | PREP 1598/4885PADI1 4142/4885PADI4 3364/4885 |
| US-20100189687-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | PREP 1598/4885PADI1 4142/4885PADI4 3364/4885 |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | PREP 1598/4885PADI1 4142/4885PADI4 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.